{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:28:09Z","timestamp":1788402489692,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,14]]},"DOI":"10.7759\/cureus.71451","type":"journal-article","created":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:19:57Z","timestamp":1728908397000},"source":"Crossref","is-referenced-by-count":12,"title":["Diagnosis and Management of Lean Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Systematic Review"],"prefix":"10.7759","author":[{"given":"Basile","family":"Njei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prince","family":"Ameyaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yazan","family":"Al-Ajlouni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lea-Pearl","family":"Njei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarpong","family":"Boateng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani N","year":"2018","unstructured":"Chalasani N, Younossi Z, Lavine JE, et al.. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018, 67:328-57. 10.1002\/hep.29367","journal-title":"Hepatology"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15353","article-title":"A review of non-alcoholic fatty liver disease in non-obese and lean individuals","volume":"36","author":"Ahadi M","year":"2021","unstructured":"Ahadi M, Molooghi K, Masoudifar N, Namdar AB, Vossoughinia H, Farzanehfar M. A review of non-alcoholic fatty liver disease in non-obese and lean individuals. J Gastroenterol Hepatol. 2021, 36:1497-507. 10.1111\/jgh.15353","journal-title":"J Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2023.101133","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"29","author":"Rinella ME","year":"2024","unstructured":"Rinella ME, Lazarus JV, Ratziu V, et al.. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Ann Hepatol. 2024, 29:101133. 10.1016\/j.aohep.2023.101133","journal-title":"Ann Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2021.04.008","article-title":"Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease","volume":"32","author":"Lim S","year":"2021","unstructured":"Lim S, Kim JW, Targher G. Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease. Trends Endocrinol Metab. 2021, 32:500-14. 10.1016\/j.tem.2021.04.008","journal-title":"Trends Endocrinol Metab"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.07.016","article-title":"Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study","volume":"20","author":"Ahmed OT","year":"2022","unstructured":"Ahmed OT, Gidener T, Mara KC, Larson JJ, Therneau TM, Allen AM. Natural history of nonalcoholic fatty liver disease with normal body mass index: a population-based study. Clin Gastroenterol Hepatol. 2022, 20:1374-81.e6. 10.1016\/j.cgh.2021.07.016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(22)00165-0","article-title":"The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis","volume":"7","author":"Riazi K","year":"2022","unstructured":"Riazi K, Azhari H, Charette JH, et al.. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2022, 7:851-61. 10.1016\/s2468-1253(22)00165-0","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.12.002","article-title":"2019 global NAFLD prevalence: a systematic review and meta-analysis","volume":"20","author":"Le MH","year":"2022","unstructured":"Le MH, Yeo YH, Li X, et al.. 2019 global NAFLD prevalence: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2022, 20:2809-17.e28. 10.1016\/j.cgh.2021.12.002","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi ZM","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016, 64:73-84. 10.1002\/hep.28431","journal-title":"Hepatology"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.113331","article-title":"Recent advances in lean NAFLD","volume":"153","author":"Xu R","year":"2022","unstructured":"Xu R, Pan J, Zhou W, Ji G, Dang Y. Recent advances in lean NAFLD. Biomed Pharmacother. 2022, 153:113331. 10.1016\/j.biopha.2022.113331","journal-title":"Biomed Pharmacother"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2022.06.023","article-title":"AGA clinical practice update: diagnosis and management of\u00a0nonalcoholic fatty liver disease in lean individuals: expert\u00a0review","volume":"163","author":"Long MT","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of\u00a0nonalcoholic fatty liver disease in lean individuals: expert\u00a0review. Gastroenterology. 2022, 163:764-74.e1. 10.1053\/j.gastro.2022.06.023","journal-title":"Gastroenterology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye Q","year":"2020","unstructured":"Ye Q, Zou B, Yeo YH, et al.. Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020, 5:739-52. 10.1016\/s2468-1253(20)30077-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2018.08.008","article-title":"Lean non-alcoholic fatty liver disease","volume":"38","author":"Wang AY","year":"2019","unstructured":"Wang AY, Dhaliwal J, Mouzaki M. Lean non-alcoholic fatty liver disease. Clin Nutr. 2019, 38:975-81. 10.1016\/j.clnu.2018.08.008","journal-title":"Clin Nutr"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i42.6514","article-title":"Nonalcoholic fatty liver disease in lean subjects: prognosis, outcomes and management","volume":"26","author":"Chrysavgis L","year":"2020","unstructured":"Chrysavgis L, Ztriva E, Protopapas A, Tziomalos K, Cholongitas E. Nonalcoholic fatty liver disease in lean subjects: prognosis, outcomes and management. World J Gastroenterol. 2020, 26:6514-28. 10.3748\/wjg.v26.i42.6514","journal-title":"World J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1677517","article-title":"NASH in lean individuals","volume":"39","author":"Younes R","year":"2019","unstructured":"Younes R, Bugianesi E. NASH in lean individuals. Semin Liver Dis. 2019, 39:86-95. 10.1055\/s-0038-1677517","journal-title":"Semin Liver Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0035","article-title":"Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity","volume":"29","author":"Kim HK","year":"2023","unstructured":"Kim HK, Bae SJ, Lee MJ, et al.. Association of visceral fat obesity, sarcopenia, and myosteatosis with non-alcoholic fatty liver disease without obesity. Clin Mol Hepatol. 2023, 29:987-1001. 10.3350\/cmh.2023.0035","journal-title":"Clin Mol Hepatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2023.0250","article-title":"Lean or non-obese nonalcoholic fatty liver disease patients: are they really lean?","volume":"29","author":"Han E","year":"2023","unstructured":"Han E, Lee YH. Lean or non-obese nonalcoholic fatty liver disease patients: are they really lean?. Clin Mol Hepatol. 2023, 29:980-3. 10.3350\/cmh.2023.0250","journal-title":"Clin Mol Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.02.040","article-title":"Waist\/hip ratio better predicts development of severe liver disease within 20 years than body mass index: a population-based cohort study","volume":"15","author":"Andreasson A","year":"2017","unstructured":"Andreasson A, Carlsson AC, \u00d6nnerhag K, Hagstr\u00f6m H. Waist\/hip ratio better predicts development of severe liver disease within 20 years than body mass index: a population-based cohort study. Clin Gastroenterol Hepatol. 2017, 15:1294-301.e2. 10.1016\/j.cgh.2017.02.040","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23576","article-title":"Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity","volume":"30","author":"Han E","year":"2022","unstructured":"Han E, Kim MK, Lee HW, Ryu S, Kim HS, Jang BK, Suh Y. Muscle fat contents rather than muscle mass determines nonalcoholic steatohepatitis and liver fibrosis in patients with severe obesity. Obesity (Silver Spring). 2022, 30:2440-9. 10.1002\/oby.23576","journal-title":"Obesity (Silver Spring)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2007.09.009","article-title":"Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents","volume":"40","author":"D\u00e2maso AR","year":"2008","unstructured":"D\u00e2maso AR, do Prado WL, de Piano A, et al.. Relationship between nonalcoholic fatty liver disease prevalence and visceral fat in obese adolescents. Dig Liver Dis. 2008, 40:132-9. 10.1016\/j.dld.2007.09.009","journal-title":"Dig Liver Dis"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13069","article-title":"Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016","volume":"288","author":"Zou B","year":"2020","unstructured":"Zou B, Yeo YH, Nguyen VH, Cheung R, Ingelsson E, Nguyen MH. Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016. J Intern Med. 2020, 288:139-51. 10.1111\/joim.13069","journal-title":"J Intern Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.11.019","article-title":"Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"21","author":"Ha J","year":"2023","unstructured":"Ha J, Yim SY, Karagozian R. Mortality and liver-related events in lean versus non-lean nonalcoholic fatty liver disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2023, 21:2496-507.e5. 10.1016\/j.cgh.2022.11.019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2337\/cd18-0026","article-title":"Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality","volume":"37","author":"Golabi P","year":"2019","unstructured":"Golabi P, Paik J, Fukui N, Locklear CT, de Avilla L, Younossi ZM. Patients with lean nonalcoholic fatty liver disease are metabolically abnormal and have a higher risk for mortality. Clin Diabetes. 2019, 37:65-72. 10.2337\/cd18-0026","journal-title":"Clin Diabetes"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi Z","year":"2018","unstructured":"Younossi Z, Anstee QM, Marietti M, et al.. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018, 15:11-20. 10.1038\/nrgastro.2017.109","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne JA","year":"2019","unstructured":"Sterne JA, Savovi\u0107 J, Page MJ, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019, 366:l4898. 10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0206450","article-title":"Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study","volume":"13","author":"Adams LC","year":"2018","unstructured":"Adams LC, L\u00fcbbe F, Bressem K, Wagner M, Hamm B, Makowski MR. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: a case-control study. PLoS One. 2018, 13:e0206450. 10.1371\/journal.pone.0206450","journal-title":"PLoS One"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v26.i15.1792","article-title":"Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease","volume":"26","author":"Zeng J","year":"2020","unstructured":"Zeng J, Yang RX, Sun C, et al.. Prevalence, clinical characteristics, risk factors, and indicators for lean Chinese adults with nonalcoholic fatty liver disease. World J Gastroenterol. 2020, 26:1792-804. 10.3748\/wjg.v26.i15.1792","journal-title":"World J Gastroenterol"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.2478\/jtim-2019-0023","article-title":"Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient","volume":"7","author":"Alam S","year":"2019","unstructured":"Alam S, Jahid Hasan M, Khan MA, Alam M, Hasan N. Effect of weight reduction on histological activity and fibrosis of lean nonalcoholic steatohepatitis patient. J Transl Int Med. 2019, 7:106-14. 10.2478\/jtim-2019-0023","journal-title":"J Transl Int Med"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study","volume":"116","author":"Lee JI","year":"2021","unstructured":"Lee JI, Lee HW, Lee KS, Lee HS, Park JY. Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a nationwide nested case-control study. Am J Gastroenterol. 2021, 116:116-24. 10.14309\/ajg.0000000000000845","journal-title":"Am J Gastroenterol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2011.06774.x","article-title":"Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease","volume":"26","author":"Adams LA","year":"2011","unstructured":"Adams LA, George J, Bugianesi E, et al.. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2011, 26:1536-43. 10.1111\/j.1440-1746.2011.06774.x","journal-title":"J Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.04.020","article-title":"New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD","volume":"71","author":"Boursier J","year":"2019","unstructured":"Boursier J, Guillaume M, Leroy V, et al.. New sequential combinations of non-invasive fibrosis tests provide an accurate diagnosis of advanced fibrosis in NAFLD. J Hepatol. 2019, 71:389-96. 10.1016\/j.jhep.2019.04.020","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera L","year":"2019","unstructured":"Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterology. 2019, 156:1264-81.e4. 10.1053\/j.gastro.2018.12.036","journal-title":"Gastroenterology"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29797","article-title":"Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials","volume":"68","author":"Caussy C","year":"2018","unstructured":"Caussy C, Reeder SB, Sirlin CB, Loomba R. Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials. Hepatology. 2018, 68:763-72. 10.1002\/hep.29797","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-021-10147-0","article-title":"The metabolic profiles and body composition of lean metabolic associated fatty liver disease","volume":"15","author":"Cheng YM","year":"2021","unstructured":"Cheng YM, Kao JH, Wang CC. The metabolic profiles and body composition of lean metabolic associated fatty liver disease. Hepatol Int. 2021, 15:405-12. 10.1007\/s12072-021-10147-0","journal-title":"Hepatol Int"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.052","article-title":"Nonalcoholic fatty liver disease 2020: the state of the disease","volume":"158","author":"Cotter TG","year":"2020","unstructured":"Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020, 158:1851-64. 10.1053\/j.gastro.2020.01.052","journal-title":"Gastroenterology"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.3390\/jcm7120562","article-title":"Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients","volume":"7","author":"Denkmayr L","year":"2018","unstructured":"Denkmayr L, Feldman A, Stechemesser L, et al.. Lean patients with non-alcoholic fatty liver disease have a severe histological phenotype similar to obese patients. J Clin Med. 2018, 7:562. 10.3390\/jcm7120562","journal-title":"J Clin Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/s41366-021-00881-8","article-title":"Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity","volume":"45","author":"Drolz A","year":"2021","unstructured":"Drolz A, Wolter S, Wehmeyer MH, et al.. Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. Int J Obes (Lond). 2021, 45:2197-204. 10.1038\/s41366-021-00881-8","journal-title":"Int J Obes (Lond)"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.09.027","article-title":"Performance of simple fibrosis scores in nonobese patients with nonalcoholic fatty liver disease","volume":"18","author":"Fu C","year":"2020","unstructured":"Fu C, Wai JW, Nik Mustapha NR, et al.. Performance of simple fibrosis scores in nonobese patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2020, 18:2843-5.e2. 10.1016\/j.cgh.2019.09.027","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/nu13082772","article-title":"The other side of malnutrition in inflammatory bowel disease (IBD): non-alcoholic fatty liver disease","volume":"13","author":"Gibiino G","year":"2021","unstructured":"Gibiino G, Sartini A, Gitto S, et al.. The other side of malnutrition in inflammatory bowel disease (IBD): non-alcoholic fatty liver disease. Nutrients. 2021, 13:2772. 10.3390\/nu13082772","journal-title":"Nutrients"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00206-6","article-title":"MetALD: new opportunities to understand the role of alcohol in steatotic liver disease","volume":"8","author":"Israelsen M","year":"2023","unstructured":"Israelsen M, Torp N, Johansen S, Thiele M, Krag A. MetALD: new opportunities to understand the role of alcohol in steatotic liver disease. Lancet Gastroenterol Hepatol. 2023, 8:866-8. 10.1016\/s2468-1253(23)00206-6","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/s0016-5085(17)33644-2","article-title":"The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of cohort study","volume":"152","author":"Jaruvongvanich V","year":"2017","unstructured":"Jaruvongvanich V, Wijarnpreecha K, Ungprasert P. The utility of NAFLD fibrosis score for prediction of mortality among patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis of cohort study. Gastroenterology. 2017, 152:1081. 10.1016\/s0016-5085(17)33644-2","journal-title":"Gastroenterology"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.784221","article-title":"Magnetic resonance imaging-proton density fat fraction vs. transient elastography-controlled attenuation parameter in diagnosing non-alcoholic fatty liver disease in children and adolescents: a meta-analysis of diagnostic accuracy","volume":"9","author":"Jia S","year":"2021","unstructured":"Jia S, Zhao Y, Liu J, Guo X, Chen M, Zhou S, Zhou J. Magnetic resonance imaging-proton density fat fraction vs. transient elastography-controlled attenuation parameter in diagnosing non-alcoholic fatty liver disease in children and adolescents: a meta-analysis of diagnostic accuracy. Front Pediatr. 2021, 9:784221. 10.3389\/fped.2021.784221","journal-title":"Front Pediatr"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2023.155666","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study","volume":"147","author":"Kouvari M","year":"2023","unstructured":"Kouvari M, Valenzuela-Vallejo L, Guatibonza-Garcia V, et al.. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study. Metabolism. 2023, 147:155666. 10.1016\/j.metabol.2023.155666","journal-title":"Metabolism"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9101346","article-title":"Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges","volume":"9","author":"Kuchay MS","year":"2021","unstructured":"Kuchay MS, Mart\u00ednez-Montoro JI, Choudhary NS, Fern\u00e1ndez-Garc\u00eda JC, Ramos-Molina B. Non-alcoholic fatty liver disease in lean and non-obese individuals: current and future challenges. Biomedicines. 2021, 9:1346. 10.3390\/biomedicines9101346","journal-title":"Biomedicines"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.113758","article-title":"Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?","volume":"17","author":"Kumar R","year":"2013","unstructured":"Kumar R, Rastogi A, Sharma MK, Bhatia V, Garg H, Bihari C, Sarin SK. Clinicopathological characteristics and metabolic profiles of non-alcoholic fatty liver disease in Indian patients with normal body mass index: do they differ from obese or overweight non-alcoholic fatty liver disease?. Indian J Endocrinol Metab. 2013, 17:665-71. 10.4103\/2230-8210.113758","journal-title":"Indian J Endocrinol Metab"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i23.7392","article-title":"Radiologic evaluation of nonalcoholic fatty liver disease","volume":"20","author":"Lee SS","year":"2014","unstructured":"Lee SS, Park SH. Radiologic evaluation of nonalcoholic fatty liver disease. World J Gastroenterol. 2014, 20:7392-402. 10.3748\/wjg.v20.i23.7392","journal-title":"World J Gastroenterol"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.5114\/amsad.2019.87122","article-title":"Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population","volume":"4","author":"Li H","year":"2019","unstructured":"Li H, Chen Y, Tian X, Hong Y, Chen C, Sharokh NK, Jiao J. Comparison of clinical characteristics between lean and obese nonalcoholic fatty liver disease in the northeast Chinese population. Arch Med Sci Atheroscler Dis. 2019, 4:e191-5. 10.5114\/amsad.2019.87122","journal-title":"Arch Med Sci Atheroscler Dis"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-317593","article-title":"Advances in non-invasive assessment of hepatic fibrosis","volume":"69","author":"Loomba R","year":"2020","unstructured":"Loomba R, Adams LA. Advances in non-invasive assessment of hepatic fibrosis. Gut. 2020, 69:1343-52. 10.1136\/gutjnl-2018-317593","journal-title":"Gut"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100293","article-title":"Embedding assessment of liver fibrosis into routine diabetic review in primary care","volume":"3","author":"Mansour D","year":"2021","unstructured":"Mansour D, Grapes A, Herscovitz M, et al.. Embedding assessment of liver fibrosis into routine diabetic review in primary care. JHEP Rep. 2021, 3:100293. 10.1016\/j.jhepr.2021.100293","journal-title":"JHEP Rep"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.25122\/jml-2018-0031","article-title":"The role of anthropometric indices in the prediction of non-alcoholic fatty liver disease in the PERSIAN Guilan Cohort study (PGCS)","volume":"11","author":"Mansour-Ghanaei R","year":"2018","unstructured":"Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F, Atrkar-Roushan Z, Tabatabaii M, Ghorani N. The role of anthropometric indices in the prediction of non-alcoholic fatty liver disease in the PERSIAN Guilan Cohort study (PGCS). J Med Life. 2018, 11:194-202. 10.25122\/jml-2018-0031","journal-title":"J Med Life"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izad175","article-title":"Inflammatory bowel disease is an independent risk factor for metabolic dysfunction-associated steatotic liver disease in lean individuals","volume":"30","author":"Mart\u00ednez-Dom\u00ednguez SJ","year":"2024","unstructured":"Mart\u00ednez-Dom\u00ednguez SJ, Garc\u00eda-Mateo S, Gargallo-Puyuelo CJ, et al.. Inflammatory bowel disease is an independent risk factor for metabolic dysfunction-associated steatotic liver disease in lean individuals. Inflamm Bowel Dis. 2024, 30:1274-83. 10.1093\/ibd\/izad175","journal-title":"Inflamm Bowel Dis"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.005","article-title":"Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis","volume":"153","author":"Middleton MS","year":"2017","unstructured":"Middleton MS, Heba ER, Hooker CA, et al.. Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis. Gastroenterology. 2017, 153:753-61. 10.1053\/j.gastro.2017.06.005","journal-title":"Gastroenterology"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i28.9330","article-title":"Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations","volume":"20","author":"Mili\u0107 S","year":"2014","unstructured":"Mili\u0107 S, Luli\u0107 D, \u0160timac D. Non-alcoholic fatty liver disease and obesity: biochemical, metabolic and clinical presentations. World J Gastroenterol. 2014, 20:9330-7. 10.3748\/wjg.v20.i28.9330","journal-title":"World J Gastroenterol"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-021-01184-6","article-title":"Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease","volume":"40","author":"Navarroza AM","year":"2021","unstructured":"Navarroza AM, Wong SN. Comparison of clinical and metabolic profiles of lean versus non-lean nonalcoholic fatty liver disease. Indian J Gastroenterol. 2021, 40:380-8. 10.1007\/s12664-021-01184-6","journal-title":"Indian J Gastroenterol"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1583366","article-title":"Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD)","volume":"54","author":"\u00d6nnerhag K","year":"2019","unstructured":"\u00d6nnerhag K, Hartman H, Nilsson PM, Lindgren S. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD). Scand J Gastroenterol. 2019, 54:328-34. 10.1080\/00365521.2019.1583366","journal-title":"Scand J Gastroenterol"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1111\/obr.12628","article-title":"Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese","volume":"19","author":"Ooi GJ","year":"2018","unstructured":"Ooi GJ, Mgaieth S, Eslick GD, Burton PR, Kemp WW, Roberts SK, Brown WA. Systematic review and meta-analysis: non-invasive detection of non-alcoholic fatty liver disease related fibrosis in the obese. Obes Rev. 2018, 19:281-94. 10.1111\/obr.12628","journal-title":"Obes Rev"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1007\/s00261-021-03269-4","article-title":"Liver fibrosis assessment: MR and US elastography","volume":"47","author":"Ozturk A","year":"2022","unstructured":"Ozturk A, Olson MC, Samir AE, Venkatesh SK. Liver fibrosis assessment: MR and US elastography. Abdom Radiol (NY). 2022, 47:3037-50. 10.1007\/s00261-021-03269-4","journal-title":"Abdom Radiol (NY)"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu V","year":"2005","unstructured":"Ratziu V, Charlotte F, Heurtier A, et al.. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology. 2005, 128:1898-906. 10.1053\/j.gastro.2005.03.084","journal-title":"Gastroenterology"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.774079","article-title":"MAFLD\/NAFLD biopsy-free scoring systems for hepatic steatosis, NASH, and fibrosis diagnosis","volume":"8","author":"Segura-Azuara NL\u00c1","year":"2021","unstructured":"Segura-Azuara NL\u00c1, Varela-Chinchilla CD, Trinidad-Calder\u00f3n PA. MAFLD\/NAFLD biopsy-free scoring systems for hepatic steatosis, NASH, and fibrosis diagnosis. Front Med (Lausanne). 2021, 8:774079. 10.3389\/fmed.2021.774079","journal-title":"Front Med (Lausanne)"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13543","article-title":"Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan","volume":"50","author":"Shida T","year":"2020","unstructured":"Shida T, Oshida N, Suzuki H, et al.. Clinical and anthropometric characteristics of non-obese non-alcoholic fatty liver disease subjects in Japan. Hepatol Res. 2020, 50:1032-46. 10.1111\/hepr.13543","journal-title":"Hepatol Res"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2021.06.042","article-title":"Liver fibrosis in Asians with metabolic dysfunction-associated fatty liver disease","volume":"20","author":"Sohn W","year":"2022","unstructured":"Sohn W, Kwon HJ, Chang Y, Ryu S, Cho YK. Liver fibrosis in Asians with metabolic dysfunction-associated fatty liver disease. Clin Gastroenterol Hepatol. 2022, 20:e1135-48. 10.1016\/j.cgh.2021.06.042","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14401","article-title":"Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease","volume":"47","author":"Sookoian S","year":"2018","unstructured":"Sookoian S, Pirola CJ. Systematic review with meta-analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2018, 47:16-25. 10.1111\/apt.14401","journal-title":"Aliment Pharmacol Ther"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2021.100382","article-title":"Strategies for a two-step liver fibrosis assessment in clinical practice","volume":"4","author":"Vieira Barbosa J","year":"2022","unstructured":"Vieira Barbosa J, Lai M. Strategies for a two-step liver fibrosis assessment in clinical practice. JHEP Rep. 2022, 4:100382. 10.1016\/j.jhepr.2021.100382","journal-title":"JHEP Rep"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi ZM","year":"2012","unstructured":"Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, Srishord M. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore). 2012, 91:319-27. 10.1097\/MD.0b013e3182779d49","journal-title":"Medicine (Baltimore)"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.05.033","article-title":"Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome","volume":"51","author":"Abid A","year":"2009","unstructured":"Abid A, Taha O, Nseir W, Farah R, Grosovski M, Assy N. Soft drink consumption is associated with fatty liver disease independent of metabolic syndrome. J Hepatol. 2009, 51:918-24. 10.1016\/j.jhep.2009.05.033","journal-title":"J Hepatol"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander M","year":"2019","unstructured":"Alexander M, Loomis AK, van der Lei J, et al.. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019, 17:95. 10.1186\/s12916-019-1321-x","journal-title":"BMC Med"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1007\/s00204-016-1892-7","article-title":"Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD)","volume":"91","author":"Alwahsh SM","year":"2017","unstructured":"Alwahsh SM, Gebhardt R. Dietary fructose as a risk factor for non-alcoholic fatty liver disease (NAFLD). Arch Toxicol. 2017, 91:1545-63. 10.1007\/s00204-016-1892-7","journal-title":"Arch Toxicol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1186\/s12199-020-00857-6","article-title":"Influence of increased physical activity without body weight loss on hepatic inflammation in patients with nonalcoholic fatty liver disease","volume":"25","author":"Asada F","year":"2020","unstructured":"Asada F, Nomura T, Hosui A, Kubota M. Influence of increased physical activity without body weight loss on hepatic inflammation in patients with nonalcoholic fatty liver disease. Environ Health Prev Med. 2020, 25:18. 10.1186\/s12199-020-00857-6","journal-title":"Environ Health Prev Med"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0046819","article-title":"Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults","volume":"7","author":"Bae JC","year":"2012","unstructured":"Bae JC, Suh S, Park SE, et al.. Regular exercise is associated with a reduction in the risk of NAFLD and decreased liver enzymes in individuals with NAFLD independent of obesity in Korean adults. PLoS One. 2012, 7:e46819. 10.1371\/journal.pone.0046819","journal-title":"PLoS One"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.101643","article-title":"Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"48","author":"Bisaccia G","year":"2023","unstructured":"Bisaccia G, Ricci F, Khanji MY, et al.. Cardiovascular morbidity and mortality related to non-alcoholic fatty liver disease: a systematic review and meta-analysis. Curr Probl Cardiol. 2023, 48:101643. 10.1016\/j.cpcardiol.2023.101643","journal-title":"Curr Probl Cardiol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.12.001","article-title":"Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes","volume":"16","author":"Bril F","year":"2018","unstructured":"Bril F, Kalavalapalli S, Clark VC, et al.. Response to pioglitazone in patients with nonalcoholic steatohepatitis with vs without type 2 diabetes. Clin Gastroenterol Hepatol. 2018, 16:558-66.e2. 10.1016\/j.cgh.2017.12.001","journal-title":"Clin Gastroenterol Hepatol"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2022-003066","article-title":"Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus","volume":"11","author":"Chen N","year":"2023","unstructured":"Chen N, Zhou J, Wang K, Li X, Li Z. Non-obese or lean non-alcoholic fatty liver disease was associated with increased risk of cancer in patients with type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2023, 11:e003066. 10.1136\/bmjdrc-2022-003066","journal-title":"BMJ Open Diabetes Res Care"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-018-0736-0","article-title":"Weight reduction and pioglitazone are cost-effective for the treatment of non-alcoholic fatty liver disease in Thailand","volume":"37","author":"Chongmelaxme B","year":"2019","unstructured":"Chongmelaxme B, Phisalprapa P, Sawangjit R, Dilokthornsakul P, Chaiyakunapruk N. Weight reduction and pioglitazone are cost-effective for the treatment of non-alcoholic fatty liver disease in Thailand. Pharmacoeconomics. 2019, 37:267-78. 10.1007\/s40273-018-0736-0","journal-title":"Pharmacoeconomics"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.3390\/nu15102250","article-title":"Does the Mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials","volume":"15","author":"Del Bo' C","year":"2023","unstructured":"Del Bo' C, Perna S, Allehdan S, et al.. Does the Mediterranean diet have any effect on lipid profile, central obesity and liver enzymes in non-alcoholic fatty liver disease (NAFLD) subjects? A systematic review and meta-analysis of randomized control trials. Nutrients. 2023, 15:2250. 10.3390\/nu15102250","journal-title":"Nutrients"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.108984","article-title":"Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial","volume":"178","author":"Della Pepa G","year":"2021","unstructured":"Della Pepa G, Russo M, Vitale M, et al.. Pioglitazone even at low dosage improves NAFLD in type 2 diabetes: clinical and pathophysiological insights from a subgroup of the TOSCA.IT randomised trial. Diabetes Res Clin Pract. 2021, 178:108984. 10.1016\/j.diabres.2021.108984","journal-title":"Diabetes Res Clin Pract"},{"key":"ref75","doi-asserted-by":"publisher","DOI":"10.1097\/MCO.0000000000000317","article-title":"Lean, but not healthy: the \u2018metabolically obese, normal-weight\u2019 phenotype","volume":"19","author":"Ding C","year":"2016","unstructured":"Ding C, Chan Z, Magkos F. Lean, but not healthy: the \u2018metabolically obese, normal-weight\u2019 phenotype. Curr Opin Clin Nutr Metab Care. 2016, 19:408-17. 10.1097\/MCO.0000000000000317","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.3390\/nu13093042","article-title":"Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: systematic review with meta-analysis of observational studies","volume":"13","author":"Ebadi M","year":"2021","unstructured":"Ebadi M, Ip S, Bhanji RA, Montano-Loza AJ. Effect of coffee consumption on non-alcoholic fatty liver disease incidence, prevalence and risk of significant liver fibrosis: systematic review with meta-analysis of observational studies. Nutrients. 2021, 13:3042. 10.3390\/nu13093042","journal-title":"Nutrients"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-021-00507-z","article-title":"Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus","volume":"17","author":"Ferguson D","year":"2021","unstructured":"Ferguson D, Finck BN. Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus. Nat Rev Endocrinol. 2021, 17:484-95. 10.1038\/s41574-021-00507-z","journal-title":"Nat Rev Endocrinol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i27.2749","article-title":"Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease","volume":"7","author":"Fukui A","year":"2015","unstructured":"Fukui A, Kawabe N, Hashimoto S, et al.. Vitamin E reduces liver stiffness in nonalcoholic fatty liver disease. World J Hepatol. 2015, 7:2749-56. 10.4254\/wjh.v7.i27.2749","journal-title":"World J Hepatol"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth K","year":"2011","unstructured":"Hallsworth K, Fattakhova G, Hollingsworth KG, et al.. Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss. Gut. 2011, 60:1278-83. 10.1136\/gut.2011.242073","journal-title":"Gut"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000001656","article-title":"Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients","volume":"32","author":"Hamurcu Varol P","year":"2020","unstructured":"Hamurcu Varol P, Kaya E, Alphan E, Yilmaz Y. Role of intensive dietary and lifestyle interventions in the treatment of lean nonalcoholic fatty liver disease patients. Eur J Gastroenterol Hepatol. 2020, 32:1352-7. 10.1097\/MEG.0000000000001656","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison SA","year":"2019","unstructured":"Harrison SA, Bashir MR, Guy CD, et al.. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019, 394:2012-24. 10.1016\/s0140-6736(19)32517-6","journal-title":"Lancet"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-023-03351-5","article-title":"Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis","volume":"85","author":"Huang S","year":"2024","unstructured":"Huang S, Bao Y, Zhang N, Niu R, Tian L. Long-term outcomes in lean and non-lean NAFLD patients: a systematic review and meta-analysis. Endocrine. 2024, 85:134-41. 10.1007\/s12020-023-03351-5","journal-title":"Endocrine"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210084","article-title":"Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease","volume":"16","author":"Kim Y","year":"2022","unstructured":"Kim Y, Han E, Lee JS, et al.. Cardiovascular risk is elevated in lean subjects with nonalcoholic fatty liver disease. Gut Liver. 2022, 16:290-9. 10.5009\/gnl210084","journal-title":"Gut Liver"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2020.154455","article-title":"The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"115","author":"Koutoukidis DA","year":"2021","unstructured":"Koutoukidis DA, Koshiaris C, Henry JA, et al.. The effect of the magnitude of weight loss on non-alcoholic fatty liver disease: a systematic review and meta-analysis. Metabolism. 2021, 115:154455. 10.1016\/j.metabol.2020.154455","journal-title":"Metabolism"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2020.10.058","article-title":"Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: results from the ATTICA prospective cohort study","volume":"40","author":"Kouvari M","year":"2021","unstructured":"Kouvari M, Boutari C, Chrysohoou C, et al.. Mediterranean diet is inversely associated with steatosis and fibrosis and decreases ten-year diabetes and cardiovascular risk in NAFLD subjects: results from the ATTICA prospective cohort study. Clin Nutr. 2021, 40:3314-24. 10.1016\/j.clnu.2020.10.058","journal-title":"Clin Nutr"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2020.1704731","article-title":"Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease","volume":"29","author":"Le P","year":"2020","unstructured":"Le P, Chaitoff A, Rothberg MB, McCullough A, Alkhouri N. Trends in pioglitazone use among U.S. adults with type 2 diabetes and suspected nonalcoholic fatty liver disease. Expert Opin Investig Drugs. 2020, 29:205-8. 10.1080\/13543784.2020.1704731","journal-title":"Expert Opin Investig Drugs"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.615409","article-title":"Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis","volume":"12","author":"Lian J","year":"2021","unstructured":"Lian J, Fu J. Pioglitazone for NAFLD patients with prediabetes or type 2 diabetes mellitus: a meta-analysis. Front Endocrinol (Lausanne). 2021, 12:615409. 10.3389\/fendo.2021.615409","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.12.053","article-title":"AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review","volume":"158","author":"Loomba R","year":"2020","unstructured":"Loomba R, Lim JK, Patton H, El-Serag HB. AGA clinical practice update on screening and surveillance for hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: expert review. Gastroenterology. 2020, 158:1822-30. 10.1053\/j.gastro.2019.12.053","journal-title":"Gastroenterology"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09621-1","article-title":"Lean NAFLD: an underrecognized and challenging disorder in medicine","volume":"22","author":"Maier S","year":"2021","unstructured":"Maier S, Wieland A, Cree-Green M, et al.. Lean NAFLD: an underrecognized and challenging disorder in medicine. Rev Endocr Metab Disord. 2021, 22:351-66. 10.1007\/s11154-020-09621-1","journal-title":"Rev Endocr Metab Disord"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3390\/nu14183791","article-title":"Combination treatment with hydroxytyrosol and vitamin E improves NAFLD-related fibrosis","volume":"14","author":"Panera N","year":"2022","unstructured":"Panera N, Braghini MR, Crudele A, et al.. Combination treatment with hydroxytyrosol and vitamin E improves NAFLD-related fibrosis. Nutrients. 2022, 14:3791. 10.3390\/nu14183791","journal-title":"Nutrients"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1016\/j.numecd.2022.07.001","article-title":"Effect of pharmacological interventions and placebo on liver histology in nonalcoholic steatohepatitis: a network meta-analysis","volume":"32","author":"Pennisi G","year":"2022","unstructured":"Pennisi G, Celsa C, Enea M, et al.. Effect of pharmacological interventions and placebo on liver histology in nonalcoholic steatohepatitis: a network meta-analysis. Nutr Metab Cardiovasc Dis. 2022, 32:2279-88. 10.1016\/j.numecd.2022.07.001","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.3390\/diseases5040023","article-title":"An overview of dietary interventions and strategies to optimize the management of non-alcoholic fatty liver disease","volume":"5","author":"Perumpail BJ","year":"2017","unstructured":"Perumpail BJ, Cholankeril R, Yoo ER, Kim D, Ahmed A. An overview of dietary interventions and strategies to optimize the management of non-alcoholic fatty liver disease. Diseases. 2017, 5:23. 10.3390\/diseases5040023","journal-title":"Diseases"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.2741\/4892","article-title":"Current treatment paradigms and emerging therapies for NAFLD\/NASH","volume":"26","author":"Raza S","year":"2021","unstructured":"Raza S, Rajak S, Upadhyay A, Tewari A, Anthony Sinha R. Current treatment paradigms and emerging therapies for NAFLD\/NASH. Front Biosci (Landmark Ed). 2021, 26:206-37. 10.2741\/4892","journal-title":"Front Biosci (Landmark Ed)"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella ME","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al.. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023, 77:1797-835. 10.1097\/HEP.0000000000000323","journal-title":"Hepatology"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.05.016","article-title":"Treatment of NAFLD with diet, physical activity and exercise","volume":"67","author":"Romero-G\u00f3mez M","year":"2017","unstructured":"Romero-G\u00f3mez M, Zelber-Sagi S, Trenell M. Treatment of NAFLD with diet, physical activity and exercise. J Hepatol. 2017, 67:829-46. 10.1016\/j.jhep.2017.05.016","journal-title":"J Hepatol"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal AJ","year":"2010","unstructured":"Sanyal AJ, Chalasani N, Kowdley KV, et al.. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med. 2010, 362:1675-85. 10.1056\/NEJMoa0907929","journal-title":"N Engl J Med"},{"key":"ref97","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2014.11.018","article-title":"Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"31","author":"Sato K","year":"2015","unstructured":"Sato K, Gosho M, Yamamoto T, et al.. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials. Nutrition. 2015, 31:923-30. 10.1016\/j.nut.2014.11.018","journal-title":"Nutrition"},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000326","article-title":"Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study","volume":"12","author":"Semmler G","year":"2021","unstructured":"Semmler G, Wernly S, Bachmayer S, et al.. Nonalcoholic fatty liver disease in lean subjects: associations with metabolic dysregulation and cardiovascular risk-a single-center cross-sectional study. Clin Transl Gastroenterol. 2021, 12:e00326. 10.14309\/ctg.0000000000000326","journal-title":"Clin Transl Gastroenterol"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000002158","article-title":"Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease","volume":"33","author":"Sinn DH","year":"2021","unstructured":"Sinn DH, Kang D, Cho SJ, Paik SW, Guallar E, Cho J, Gwak GY. Weight change and resolution of fatty liver in normal weight individuals with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2021, 33:e529-34. 10.1097\/MEG.0000000000002158","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1111\/liv.15763","article-title":"Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"44","author":"Souza M","year":"2024","unstructured":"Souza M, Diaz I, Barchetta I, Mantovani A. Gastrointestinal cancers in lean individuals with non-alcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int. 2024, 44:6-14. 10.1111\/liv.15763","journal-title":"Liver Int"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1111\/liv.12483","article-title":"Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models","volume":"35","author":"Stewart KE","year":"2015","unstructured":"Stewart KE, Haller DL, Sargeant C, Levenson JL, Puri P, Sanyal AJ. Readiness for behaviour change in non-alcoholic fatty liver disease: implications for multidisciplinary care models. Liver Int. 2015, 35:936-43. 10.1111\/liv.12483","journal-title":"Liver Int"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.06.010","article-title":"Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review","volume":"56","author":"Thoma C","year":"2012","unstructured":"Thoma C, Day CP, Trenell MI. Lifestyle interventions for the treatment of non-alcoholic fatty liver disease in adults: a systematic review. J Hepatol. 2012, 56:255-66. 10.1016\/j.jhep.2011.06.010","journal-title":"J Hepatol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.1016\/s2468-1253(23)00066-3","article-title":"Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"8","author":"Tincopa MA","year":"2023","unstructured":"Tincopa MA, Loomba R. Non-invasive diagnosis and monitoring of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Lancet Gastroenterol Hepatol. 2023, 8:660-70. 10.1016\/s2468-1253(23)00066-3","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30368","article-title":"Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis","volume":"71","author":"Vilar-Gomez E","year":"2020","unstructured":"Vilar-Gomez E, Vuppalanchi R, Gawrieh S, Ghabril M, Saxena R, Cummings OW, Chalasani N. Vitamin E improves transplant-free survival and hepatic decompensation among patients with nonalcoholic steatohepatitis and advanced fibrosis. Hepatology. 2020, 71:495-509. 10.1002\/hep.30368","journal-title":"Hepatology"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-00408-y","article-title":"Therapeutic pipeline in nonalcoholic steatohepatitis","volume":"18","author":"Vuppalanchi R","year":"2021","unstructured":"Vuppalanchi R, Noureddin M, Alkhouri N, Sanyal AJ. Therapeutic pipeline in nonalcoholic steatohepatitis. Nat Rev Gastroenterol Hepatol. 2021, 18:373-92. 10.1038\/s41575-020-00408-y","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0000000000000776","article-title":"Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"29","author":"Wijarnpreecha K","year":"2017","unstructured":"Wijarnpreecha K, Thongprayoon C, Ungprasert P. Coffee consumption and risk of nonalcoholic fatty liver disease: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2017, 29:e8-12. 10.1097\/MEG.0000000000000776","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.08.011","article-title":"Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease","volume":"69","author":"Wong VW","year":"2018","unstructured":"Wong VW, Wong GL, Chan RS, et al.. Beneficial effects of lifestyle intervention in non-obese patients with non-alcoholic fatty liver disease. J Hepatol. 2018, 69:1349-56. 10.1016\/j.jhep.2018.08.011","journal-title":"J Hepatol"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02493-z","article-title":"Correction: association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study","volume":"20","author":"Xin J","year":"2022","unstructured":"Xin J, Jiang X, Ben S, et al.. Correction: association between circulating vitamin E and ten common cancers: evidence from large-scale Mendelian randomization analysis and a longitudinal cohort study. BMC Med. 2022, 20:281. 10.1186\/s12916-022-02493-z","journal-title":"BMC Med"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi ZM","year":"2019","unstructured":"Younossi ZM, Ratziu V, Loomba R, et al.. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019, 394:2184-96. 10.1016\/S0140-6736(19)33041-7","journal-title":"Lancet"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2014.10.008","article-title":"Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population","volume":"165","author":"Zelber-Sagi S","year":"2015","unstructured":"Zelber-Sagi S, Salomone F, Webb M, et al.. Coffee consumption and nonalcoholic fatty liver onset: a prospective study in the general population. Transl Res. 2015, 165:428-36. 10.1016\/j.trsl.2014.10.008","journal-title":"Transl Res"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24965","article-title":"Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors?","volume":"24","author":"Satkunasingham J","year":"2018","unstructured":"Satkunasingham J, Nik HH, Fischer S, et al.. Can negligible hepatic steatosis determined by magnetic resonance imaging-proton density fat fraction obviate the need for liver biopsy in potential liver donors?. Liver Transpl. 2018, 24:470-7. 10.1002\/lt.24965","journal-title":"Liver Transpl"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11123477","article-title":"Mediterranean diet: the beneficial effects of lycopene in non-alcoholic fatty liver disease","volume":"11","author":"Abenavoli L","year":"2022","unstructured":"Abenavoli L, Procopio AC, Paravati MR, Costa G, Mili\u0107 N, Alcaro S, Luzza F. Mediterranean diet: the beneficial effects of lycopene in non-alcoholic fatty liver disease. J Clin Med. 2022, 11:3477. 10.3390\/jcm11123477","journal-title":"J Clin Med"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1437","article-title":"Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT)","volume":"306","author":"Klein EA","year":"2011","unstructured":"Klein EA, Thompson IM Jr, Tangen CM, et al.. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011, 306:1549-56. 10.1001\/jama.2011.1437","journal-title":"JAMA"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/267371-diagnosis-and-management-of-lean-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-systematic-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T12:20:01Z","timestamp":1728908401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/267371-diagnosis-and-management-of-lean-metabolic-dysfunction-associated-steatotic-liver-disease-masld-a-systematic-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,14]]},"references-count":113,"URL":"https:\/\/doi.org\/10.7759\/cureus.71451","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10,14]]}}}